42
Immunizati on Amha Mekasha, MD, Msc DPCH June 2012

6. immunization amha

Embed Size (px)

DESCRIPTION

IMMUNZ2

Citation preview

Page 1: 6. immunization amha

ImmunizationAmha Mekasha, MD, Msc

DPCH

June 2012

Page 2: 6. immunization amha

Session objectives

• Define types of immunity

• Describe types of vaccines

• List contraindications of vaccinations

• Identify adverse effects following immunization

• Describe cold chain in immunization

• Define some key concepts in vaccination management

Page 3: 6. immunization amha

Under 5 Deaths from Vaccine Preventable Under 5 Deaths from Vaccine Preventable Diseases - 2002Diseases - 2002

Others = Polio, YF, Hep.B, Jap encep, Meningococcal

Over 2 Over 2 Million Million

Deaths to Be Deaths to Be PreventedPrevented

Page 4: 6. immunization amha

Passive & active immunity

natural immunity artificial immunity

post- infection

active

maternal antibody

transfer to the fetus

passive

exposure to antigen

active immunisation

active

injection of antibodies

passive immunisation

passive

Page 5: 6. immunization amha

Passive immunisation

antibody donor(immune subject)

antibody recipient(non-immune subject)

antibody transfer

Page 6: 6. immunization amha

Passive immunisation

anti

bod

y co

nce

ntr

atio

n

weeks4 8 12 16 20

injection of Ig

• short-term protection

• potential safety concerns

Page 7: 6. immunization amha

Vaccination

antigen (vaccine)administered to non-immune subject

actively immunised subject

Page 8: 6. immunization amha

Active immunization

anti

bod

y co

nce

ntr

atio

n

weeks4 8 12 16 20injection of vaccine

• long-term protection

• cost-effective

• safe

Page 9: 6. immunization amha

• is affordable & accessible to all

• has an acceptable reactogenicity profile

• is immunogenic and protective

• provides long-lasting protection

• does not require frequent boosters

• can be integrated into EPI

• is stable in field use

The ideal vaccine ….

Page 10: 6. immunization amha

• reduces morbidity & mortality• is a cost-effective intervention• protection of the individual• protection of communities (herd immunity)

• control of disease• elimination of diseases• eradication of disease & the pathogen

Benefits of vaccination

Page 11: 6. immunization amha

Benefits of vaccination

20

40

60

1980 1990 2000

polio - worldwidere

po

rted

ca

ses

(000

s)

EPI implemented

1950 1960 1970 1980

measles - US

vaccine introduced

20

40

60

1940 1950 1960

Diphtheria – England & Wales

rep

ort

ed c

ase

s (0

00s

)

vaccine introduced

Page 12: 6. immunization amha

Types of vaccines

• live-attenuated vaccines– polio Sabin (OPV), measles, mumps, varicella,

yellow fever, – BCG, cholera, typhoid fever ….

• killed, inactivated vaccines– polio Salk (IPV), hepatitis A, whole cell

pertussis (Pw) ….

Page 13: 6. immunization amha

Types of vaccines

• sub-unit vaccines– diphtheria, tetanus, pertussis toxoids– purified acellular pertussis (Pa) components– genetically engineered HBsAg, HPV, malaria– polysaccharides (Vi, Men, Pneumo) – conjugated polysaccharides (Hib, Men, Pneumo)– split or sub-unit influenza vaccines H1N1,

H3N2 (H5NI)

Page 14: 6. immunization amha

Types of vaccines

• combined vaccines– DTPw-HepB (Tetra); DTPw-HepB/Hib (Penta)– DTPw-HepB/Hib-MenAC (Hepta)– DTPa-HepB-IPV/Hib– Hib-MenC; Hib-MenCY; Hib-MenAC(W?)– Men ACWY polysaccaride vaccines– MenACWY conjugate PS vaccines– HepA/Vi; HepAHepB ….

Page 15: 6. immunization amha

Live-attenuated vaccines

strain attenuation in cell culture

wild virus replication in unfavourable conditions

the process is repeatedmany times …

… to produce an attenuated strain, unable to cause disease

Page 16: 6. immunization amha

Live-attenuated vaccines

attenuated virus from the Master Working Cell Bank …

is replicated on a

large scale

then harvested, tested, and formulated into a vaccine

Page 17: 6. immunization amha

Live-attenuated vaccines

disadvantages• may retain some pathogenicity

• may revert to virulence

• may not be safe enough to vaccinate highly immuno-compromised subjects

• require a good cold chain

Page 18: 6. immunization amha

Live-attenuated vaccines

advantages

• mimic natural infection• produce a large antigenic stimulus• generally induce T&B lymphocyte responses• provide long-lasting protection

Page 19: 6. immunization amha

Killed, inactivated vaccines

the pathogen is grown under suitable conditions

purified and treated with heat or chemicals

… so that it is inactivated but still immunogenic

Page 20: 6. immunization amha

Killed, inactivated vaccines

disadvantages

• often less effective than live-attenuated vaccines

• several doses needed for long-termprotection

• repeat administration may increase reactogenicity

• limited production capacity & higher price

Page 21: 6. immunization amha

Sub-unit vaccines

toxoid production

inactivation

antigenic determinantscapable of inducing an immune response

toxic groups

toxin

toxoid

Page 22: 6. immunization amha

Sub-unit vaccines

Purified antigenic extractsacellular pertussis vaccine components

• pertussis toxoid (excreted)

• filamentous haemagglutinin (excreted)

• pertactin (69 kDa outer membrane protein)

• fimbrial antigens

Page 23: 6. immunization amha

polysaccharides

• T-cell independent Ags• not immunogenic in infants• do not induce an immune memory (no booster effect

Sub-unit vaccinesconjugated polysaccharide vaccines

conjugated PSs

• T-dependent Ags

• immunogenic in infants as of 6 weeks

• establish immune memory• strong booster effect

Page 24: 6. immunization amha

Sub-unit vaccinesrecombinant HBsAg vaccines

isolation of HBV in the 1970s

isolation of the surface antigen gene

insertion of the gene into bakers’ yeast and HBsAg expression

Page 25: 6. immunization amha

Sub-unit vaccines

multiplication of yeast cells in fermentors

the yeast cells produce surface antigen

isolation & purification of the surface antigen particles

Page 26: 6. immunization amha

Adjuvants

anti

bod

y co

nce

ntr

atio

n

weeks2 4 6 8 10vaccination

primary response in the absence of adjuvant

+ adjuvant

Page 27: 6. immunization amha

Methods of administration

subcutaneous intramuscular

intradermaloral

Page 28: 6. immunization amha

Adverse reactions

• local reactions– pain at injection site, redness

– swelling

• systemic reactions– fever, malaise ...

Page 29: 6. immunization amha

vaccine Reaction Onset interval

BCG Lymphadenitis, Ostities, Disseminated BCG

2-6 mos1-12 mos1-12 mos

HepB Anaphylaxis 0-1 hr

MMR Febrile seizure,ThrombocytopeniaAnaphylaxisEncephalopathy

6-12 hrs15-35 days0-1 hrs6-12 days

OPV Paralytic polio 4-30 days

Tetanus Brachial neuritisanaphylaxis

2-28 days0-1 hr

DPT Seizurehyptonic hyporesponsive episodesAnaphylaxisEncephalopathypersistent inconsolable screaming >3 hrs

0-2 days0-24 hrs0-1 hr0-2 days0-24 hrs

Page 30: 6. immunization amha

Contra-indications• Hypersensitivity

• Symptomatic HIV infection (BCG)

• Pregnancy (except for vaccination against neonatal tetanus)

Page 31: 6. immunization amha

A network of refrigerators, cold stores, freezers and cold boxes organized and maintained so that vaccines are kept at the right temperature to remain potent during orders, supplies, transportation, storage, distribution to the point of

administration to the target population.

Cold chain

Page 32: 6. immunization amha

Storage and distribution

live-attenuated vaccines

• vaccine (but not diluent) can be stored in a freezer or at +2°C to +8°C

• after reconstitution, use as soon as possible; discard after 6 hoursor at the end of the session

Page 33: 6. immunization amha

Cold chain

• some vaccines are cryostable (stable if frozen)

• some vaccines are cryolabile (unstable if frozen)

• most vaccines are thermolabile (unstable if exposed to temperatures above +2°C to +8°C)

• some vaccines are more thermostable than others (DTP > measles > OPV)

Page 34: 6. immunization amha

Arranging Vaccine - 1Arranging Vaccine - 1

Correct use of upright refrigerators

Page 35: 6. immunization amha

Unplanned Storage capacity needsUnplanned Storage capacity needs

Page 36: 6. immunization amha

• Never freeze BCG if the diluent and the vaccine are packed together

• Freezing causes damage to: DPT-HepB-Hib, TT, inactivated polio, HepB.

Page 37: 6. immunization amha

Definition of some key concepts

• Coverage: is the percentage of immunized individuals among the target population

• Drop out: The drop-out rate is a comparison of number of children who start the immunisation schedule and the number who complete it.

• Access: First contact with the regular immunization service (DPT1)

• Missed opportunities: Failure to provide all antigens to the child or woman of child bearing age for which he/she is eligible

Page 38: 6. immunization amha

Drop-out rate: calculation

DTP1 – DTP3 drop-out rate:

cumulative doses of DTP1 - cumulative doses of DTP3 x 100

cumulative doses of DTP1

DTP1 – Measles drop-out rate:

cumulative doses of DTP1 - cumulative doses of measles

cumulative doses of DTP1x 100

Page 39: 6. immunization amha

• Ensure continuous supply of vaccines• Rescheduling of cancelled clinics where possible• Reduce waiting time• Client education

– Number of doses – Dates for return– Possible side effects

• Establishing a system for defaulter tracing involving both HWs and Community members.

REDUCING DROP OUTS

Page 40: 6. immunization amha

Calculating vaccination coverage by antigen/vaccine

CR = CR = Doses administered for a Doses administered for a vaccinevaccine x 100 x 100

target populationtarget population

Page 41: 6. immunization amha

• Ensure screening at every opportunity• Ensure children/mothers have immunization cards to

make screening easier

• Give all vaccines due whenever a child presents

• Eliminate all false contraindications

Preventing Missed Opportunities

Page 42: 6. immunization amha

Thank you